(Q45750675)

15 December 2017

title

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice (English)

1 reference

15 December 2017

author name string

Sarin PS

1

1 reference

15 December 2017

Talmadge JE

2

1 reference

15 December 2017

Heseltine P

3

1 reference

15 December 2017

Murcar N

4

1 reference

15 December 2017

Gendelman HE

5

1 reference

15 December 2017

Coleman R

6

1 reference

15 December 2017

Kelsey L

7

1 reference

15 December 2017

Beckner S

8

1 reference

15 December 2017

Winship D

9

1 reference

15 December 2017

Kahn J

10

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

15 December 2017

published in

Vaccine

1 reference

15 December 2017

volume

17

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

64-71

1 reference

15 December 2017

HIV preventive vaccines. Progress to date

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Reexamining AIDS research priorities

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Scientific and social issues of human immunodeficiency virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Escape of human immunodeficiency virus from immune control

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

HIV-specific cellular and humoral immune responses in primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

A strategy for prophylactic vaccination against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

A Macromolecular Multicomponent Peptide Vaccine Prepared Using the Glutaraldehyde Conjugation Method with Strong Immunogenicity for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

A TH1-->TH2 switch is a critical step in the etiology of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Cytotoxic T lymphocytes against HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Human Studies in the Development of Human Immunodeficiency Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Progress in AIDS Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

Toward an understanding of the correlates of protective immunity to HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900119-4

7 January 2021

10.1016/S0264-410X(98)00119-4

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017